With PolyPeptide manufacturing peptides such as GLP-1 medicines, Samsung Biologics has identified the deal as a way to tap into fast-growing demand for obesity drug production services.

Original title: “Samsung Biologics targets $1.8B PolyPeptide buyout to expand in obesity”

The lawsuit follows a cease-and-desist request and argues Lilly is using “deceptive” ads to claim its GLP-1 products are broadly superior to Novo’s medicines. Lilly countered that its campaign is “truthful.”

Original title: “Novo sues Lilly, alleging ‘misleading’ advertising of obesity drugs”

Despite an FDA crackdown, numerous pharma lawsuits and possible safety risks, nearly 1 in 5 patients are still taking cheaper weight-loss alternatives.

Original title: “Compounders maintain a firm grip on the GLP-1 market”

Newly published data convinced AstraZeneca to conduct a sprawling late-stage program for its GLP-1 pill. Elsewhere, Bausch + Lomb will lay off 119 employees and Cartesian boosted its ‘in vivo’ cell therapy capabilities.

Original title: “AstraZeneca’s ‘extensive’ obesity drug push; $125M for ultrasound-aided genetic medicine”

Novo Nordisk and Eli Lilly presented data extolling the benefits of their relative weight loss therapies in obesity-linked indications, while analysts at BMO Capital Markets were “encouraged” by the strategy communicated by Novo management.

Original title: “ADA: Novo boasts deep pipeline, ‘breadth of assets’ after analysts award Lilly weight loss gold”

At a big meeting for weight loss drugs, Lilly’s “triple G” therapy set a new standard as lingering doubts surrounded other competing treatments.

Original title: “ADA ‘26: Lilly’s dominance, Pfizer’s ‘foundational’ drug and Roche’s ‘me-too’ option”

While survodutide’s 16.6% overall weight loss was underwhelming, Boehringer Ingelheim and Zealand Pharma’s drug achieved “impressive” fat loss, according to BMO Capital Markets.

Original title: “ADA: Boehringer leans on fat mass benefits as obesity bet delivers ‘less competitive’ weight reduction”

Much work needs to be done for Pfizer to be able to catch up to the weight-loss frontrunners, according to Guggenheim Partners, but new data from Metsera’s lead asset could set the pharma apart from competitors with a monthly injection.

Original title: “ADA: Metsera asset data support Pfizer's ‘entry point’ into obesity market”

Over two years of treatment, Eli Lilly’s triple-G drug cut body weight by more than 30% in certain patients with obesity, cementing the pharma’s position as the frontrunner in the metabolic space.

Original title: “ADA: Lilly sets ‘new record in Weight Loss Olympics’ with next-gen asset”

The American Diabetes Association's annual congress will feature a superstar lineup, including weight loss giants Eli Lilly and Novo Nordisk. But several scrappy biotechs will also present obesity candidates with the potential to match—if not outperform—their deep-pocketed competitors.

Original title: “Lilly and Novo face off at ADA 2026 as others seek to compete in obesity”

The anti-aging biotech has secured one of the year’s biggest venture fundings to bring its first drug into testing. Elsewhere, Lilly nabbed a “GLP-2” obesity drug and Praxis shares tumbled.

Original title: “NewLimit’s $435M megaround; Lilly’s busy dealmaking week”

The American Diabetes Association's annual congress will feature a superstar lineup, including weight loss giants Eli Lilly and Novo Nordisk. But several scrappy biotechs will also present obesity candidates with the potential to match—if not outperform—their deep-pocketed competitors.

Original title: “Obesity Davids and Goliaths face off at ADA 2026”

After trial flops in spinal muscular atrophy, depression and bipolar disorder—and a costly rare disease drug rejection—Biohaven is undergoing a reset, recasting its former SMA candidate for obesity.

Original title: “Biohaven looks to obesity to bounce back from run of clinical and regulatory failures”

The agreement includes Lilly’s new pill Foundayo and restores coverage for Zepbound, erasing what had been a commercial edge for rival Novo Nordisk.

Original title: “CVS obesity drug deal puts Lilly on equal footing with Novo”

The Food and Drug Administration (FDA) is classifying the endoscopic suturing device for altering gastric anatomy for weight loss into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for classification of the endoscopic suturing device for altering gastric anatomy for weight loss. We are taking this action because we have determined that classifying the device into class II will provide a reaso

Original title: “Medical Devices; Gastroenterology-Urology Devices; Classification of the Endoscopic Suturing Device for Altering Gastric Anatomy for Weight Loss”

Participants who stayed on the drug lost around one-quarter of their body weight, potentially setting a new benchmark for rivals like Novo Nordisk.

Original title: “Lilly’s triple-acting obesity drug hits goal in Phase 3 trial”

Lilly met analysts’ sky-high expectations with 28.3% weight loss over 80 weeks for the triple hormone receptor agonist retatrutide in a highly anticipated readout on Thursday.

Original title: “Lilly’s triple agonist shows bariatric surgery–like weight loss results”

The agency has once again shuffled the leadership for two top drug review offices. Elsewhere, Parabilis partnered with Regeneron and an obesity pill is headed toward an approval in China.

Original title: “Høeg fired in latest FDA shakeup; 20 people die after taking Amgen drug”

A pair of trial results published in medical journals suggest switching from high-dose injectables to lower doses or pills could help people with obesity keep their weight down over the long term.

Original title: “Lilly data point to ‘maintenance’ strategies for GLP-1 weight loss”

Despite seeing some regain, patients in two trials maintained most of their weight loss after switching to either Foundayo or lower-dose Zepbound from other injectable incretin therapies.

Original title: “Lilly maintains weight loss leadership as Foundayo, Zepbound keep pounds off after switching”